Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · INDSWFTLAB

IND-SWIFT LA

HealthcarePharmaceuticals & Biotechnology₹2921 cr market cap
₹330.25 ▼ -1.93% today As of 19 Nov 2026
52-week low ₹88.1552-week high ₹413.10

-18.5% from the 52-week high · +282.0% above the low

Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm is in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates, and formulations. The firm operates one business segment viz. Bulk Drugs and Pharmaceuticals. The company offers three products or services, which includes APIs, Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The company has two manufacturing facilities and one Research Centre. Its API business caters to the needs of the regulated markets, including USA, Europe, Korea, Japan and Latin America. Its research and development (R&D) center is primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. Its products under API include Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, Parkinson’s Disease, Hyperparathyroidism, Analgesic (Controlled Substances), and Aromatase Inhibitor.

The short version. IND-SWIFT LA reported revenue of ₹240 crore for Sep 2026, up 56.9% from a year earlier. Net profit was ₹34 crore (up 325.0% year on year). Return on equity was 3.0% in Mar 2026. Promoter holding was 42.93% in Sep 2026, up 0.93 points over 8 quarters.

1 · The price

How has the stock traded?

IND-SWIFT LA trades 18.5% below its 52-week high and 282.0% above its 52-week low.

Change over period: —

1M-4.3%
3M+4.6%
6M+147.8%
1Y+248.6%

2 · The business

Is it growing?

Sales, year on year+56.9%

Sep 2026 revenue of ₹240 cr.

Profit, year on year+325.0%

Sep 2026 net profit of ₹34 cr.

Net margin14.2%

9.0 pts higher than a year earlier.

3-year growth-4.5% profit

Revenue compounded at -17.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2401911701511531531389
Net profit34251510892220
Net margin %14.212.98.96.35.25.7160.80.1
EPS (₹)3.942.841.741.170.981.4536.670.0

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue641562128112071039891780757
Net profit4125042148-2-3-2138
Net margin %6.544.632.93.9-0.2-0.4-2.75.1
EPS (₹)4.7741.3271.338.06-0.36-0.53-3.598.08

3 · The quality

How well does it turn capital into profit?

Return on equity was 3.0% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %3.021.345.27.0
Return on capital %3.621.467.012.3
EBITDA margin %11.844.451.719.0
Net margin %6.039.031.83.8

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-17.8%-5.5%
Profit CAGR-4.5%—
Debt to equity0.01
Interest cover35.9x
Current ratio3.83
P/E ratio34.8

4 · The owners

Who holds it, and are they adding?

Promoter holding42.93%

Up 0.93 pts over 8 quarters.

Foreign institutions10.78%

Up 10.32 pts over 8 quarters.

Domestic institutions0.2%

Down 0.74 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter42.040.9440.9439.539.542.9942.9342.93+0.93
FII0.463.074.2714.814.3313.8810.710.78+10.32
DII0.940.910.910.680.6800.170.2-0.74
Public56.655.0753.8745.0245.543.1246.246.09-10.51

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.11% of NAV
  • Bandhan BSE Healthcare Index Fund0.11% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for IND-SWIFT LA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about IND-SWIFT LA

What is the IND-SWIFT LA share price?

IND-SWIFT LA (INDSWFTLAB) last closed at ₹330.25, down 1.93% on the day. Its 52-week range is ₹88.15 to ₹413.10.

What is the market cap of IND-SWIFT LA?

IND-SWIFT LA has a market capitalisation of about ₹2,921 crore. Its price-to-earnings ratio is 34.8.

How are IND-SWIFT LA's latest results?

IND-SWIFT LA reported revenue of ₹240 crore for Sep 2026, up 56.9% from a year earlier. Net profit was ₹34 crore (up 325.0% year on year). Return on equity was 3.0% in Mar 2026. Promoter holding was 42.93% in Sep 2026, up 0.93 points over 8 quarters.

Who owns IND-SWIFT LA?

As of Sep 2026, shareholding was: Promoter 42.93%, FII 10.78%, DII 0.2%, Public 46.09%.

How many mutual funds hold IND-SWIFT LA?

2 mutual fund schemes held IND-SWIFT LA in October 2026. That compares with 2 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.